Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CFO Sells $246,749.39 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Alnylam Pharmaceuticals Price Performance

ALNY traded down $0.41 on Friday, hitting $250.59. 649,260 shares of the stock were exchanged, compared to its average volume of 693,578. The firm has a market capitalization of $32.44 billion, a price-to-earnings ratio of -115.48 and a beta of 0.35. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The business has a 50-day moving average of $254.04 and a two-hundred day moving average of $263.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on ALNY. Wolfe Research lowered Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research report on Tuesday, November 12th. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a "buy" rating in a report on Tuesday. Scotiabank lowered their price objective on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating for the company in a research note on Friday, February 14th. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Finally, HC Wainwright reiterated a "buy" rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $299.48.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $1,045,822,000. Norges Bank purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $577,941,000. Capital Research Global Investors boosted its position in shares of Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after acquiring an additional 1,724,610 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after acquiring an additional 1,245,195 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in shares of Alnylam Pharmaceuticals by 496.6% during the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock valued at $89,100,000 after acquiring an additional 315,182 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.